This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Markham, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markham, P. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 1999, p. 988-989, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Inhibition of the Emergence of Ciprofloxacin Resistance in Streptococcus pneumoniae by the Multidrug Efflux Inhibitor Reserpine

Penelope N. Markham*

Influx, Inc., Chicago Technology Park, Chicago, Illinois 60612

Received 1 September 1998/Returned for modification 20 October 1998/Accepted 13 January 1999


    ABSTRACT
Top
Abstract
Text
References

Recent evidence supports the contribution of a multidrug efflux mechanism to fluoroquinolone resistance in Streptococcus pneumoniae. In this paper I show that reserpine, an inhibitor of multidrug transporters in gram-positive bacteria, dramatically suppresses the in vitro emergence of ciprofloxacin-resistant variants of S. pneumoniae, suggesting that the combination of a fluoroquinolone with an inhibitor of multidrug transport may help preserve the efficacy of this class of antibiotics.


    TEXT
Top
Abstract
Text
References

Many chromosomally encoded multidrug transporters have recently been identified in gram-positive bacteria, including Bmr and Blt in Bacillus subtilis (1, 10), NorA in Staphylococcus aureus (13), LmrA and LmrP in Lactococcus lactis (3, 12), and LfrA in Mycobacterium smegmatis (11). These proteins transport structurally diverse compounds, including fluoroquinolone antibiotics and toxic cations such as ethidium bromide and rhodamine, out of cells, thereby preventing their intracellular accumulation. The activities of many of these pumps can be inhibited by the alkaloid reserpine. Studies with S. aureus have demonstrated that reserpine potentiates fluoroquinolone bacteriotoxicity in wild-type cells, reverses NorA-mediated fluoroquinolone resistance in clinical isolates, and suppresses the emergence of fluoroquinolone-resistant variants (6, 7).

Recent evidence indicates the presence of a reserpine-sensitive multidrug transporter in the respiratory pathogen Streptococcus pneumoniae (2). Expression of this putative efflux transporter augments resistance to the fluoroquinolones ciprofloxacin and norfloxacin, as well as to ethidium bromide and acriflavine (2, 4, 14). To date, this efflux mechanism has been detected in the following: (i) wild-type strains, where it appears to contribute to the decreased intrinsic susceptibility of this pathogen to fluoroquinolones (2, 5); (ii) a strain selected for increased resistance to the multidrug transporter substrate ethidium bromide (2); and (iii) first-step spontaneous mutants selected in vitro for low-level fluoroquinolone resistance (4, 5, 14). Importantly, this efflux mechanism appears to be a prevalent cause of clinically significant fluoroquinolone resistance in S. pneumoniae. Brenwald et al. very recently reported that almost half of isolates showing a reduced susceptibility to the fluoroquinolones norfloxacin and ciprofloxacin exhibit a reserpine-sensitive drug resistance phenotype consistent with the expression of PmrA (5). I speculated that, similar to previous findings with S. aureus (7), reserpine would be found to inhibit the emergence of fluoroquinolone resistance in S. pneumoniae.

Single-step mutants of S. pneumoniae (ATCC 49619) resistant to three- or fourfold the MIC of ciprofloxacin (1.5 or 2 µg/ml) were selected in vitro, in either the absence or presence of reserpine at a concentration of 10 µg/ml. Approximately 2 × 109 cells were plated on Mueller-Hinton agar plates containing 10% lysed horse blood and were incubated for 72 h at 37°C in an oxygen-reduced atmosphere. Susceptibility testing of mutants was conducted by using broth microdilution assays (9). Sequence analysis of the amplified quinolone resistance determining region (QRDR) of parC was performed essentially as previously described (8). PCR products were purified with the Wizard PCR system (Promega), and sequencing was performed with the fmol DNA sequencing system (Promega).

The emergence of ciprofloxacin resistance was strikingly suppressed in the presence of reserpine. Whereas in the absence of reserpine 135 colonies of S. pneumoniae ATCC 49619 were obtained in medium containing three times the MIC of ciprofloxacin and 19 colonies were obtained in four times the MIC of ciprofloxacin, in the presence of reserpine only 3 colonies resistant to three times the MIC (a 45-fold reduction) were obtained, and no colonies resistant to four times the MIC were obtained. This dramatic effect could not be attributed to a toxic effect of reserpine. The MIC of reserpine for strain ATCC 49619 is greater than 40 µg/ml, the solubility limit for this drug in cation-adjusted Mueller-Hinton broth. Additionally, reserpine affected neither the colony-forming ability nor the colony size of S. pneumoniae plated in the absence of ciprofloxacin.

One possible explanation for the observed effect of reserpine is that the augmented fluoroquinolone resistance in the majority of first-step selected mutants is reserpine sensitive. Indeed, this proved to be the case. The MIC of ciprofloxacin was at least eightfold higher than that for the wild-type strain (4 to 8 versus 0.5 µg/ml) (Table 1) for 10 mutants evaluated. Importantly, the MIC of ciprofloxacin for eight of these mutants was reduced to 1 µg/ml or less in the presence of 10 µg of reserpine per ml. Consistent with the expression of a multidrug efflux mechanism, resistance to the multidrug transporter substrate ethidium bromide was also augmented (fourfold) in a reserpine-sensitive manner. Interestingly, two different phenotypes were distinguishable by the sensitivity of these efflux mutants to reserpine; the ciprofloxacin resistance of seven of the eight mutants was reversed fourfold by reserpine at a concentration of 2.5 to 5 µg/ml, while as little as 0.15 µg/ml, a 16- to 32-fold-lower concentration, had the same effect on the eighth mutant. This finding strongly suggests that two different multidrug transporters can contribute to ciprofloxacin resistance in S. pneumoniae.

                              
View this table:
[in this window]
[in a new window]
  		TABLE 1.   Susceptibility patterns of ciprofloxacin-resistant mutants compared to wild typea

Although reserpine, in a manner similar to its effect on the susceptible strain, increased the ciprofloxacin susceptibility of the remaining (nonefflux) mutants only twofold (MIC of ciprofloxacin, 4 µg/ml), this effect is sufficient to prevent their emergence upon selection with 2 µg of ciprofloxacin per ml. Since ethidium bromide susceptibility was unchanged in these mutants, it appeared that they possessed alterations in a different fluoroquinolone target, most likely ParC, the primary target of ciprofloxacin in S. pneumoniae (8). Indeed, sequence analysis of the amplified QRDR of parC in these mutants (8) revealed a mutation altering S-79 to Y (TCT-TAT) in one mutant and D-83 to Y (GAT-TAT) in the other mutant, residues previously reported to be altered in pneumococcal isolates resistant to low levels of ciprofloxacin (8).

The three mutants resistant to three times the MIC of ciprofloxacin in the presence of reserpine also appeared to be ParC mutants; analysis of two of these mutants revealed a mutation of S-79 to F (TCT-TTT) in the QRDR of ParC. Apparently, the slightly lower selecting concentration of ciprofloxacin (1.5 versus 2 µg/ml) allows these mutants to emerge even in the presence of reserpine.

These results indicate that the combination of a fluoroquinolone, such as ciprofloxacin, with a multidrug efflux inhibitor would substantially improve the clinical efficacy of this class of antibiotics against S. pneumoniae. Such a combination drug not only would suppress the emergence of fluoroquinone-resistant bacteria but also would be effective in a large percentage of existing resistant strains. Since similar findings have been previously reported for S. aureus, it is likely that such a combination which would be effective against a spectrum of gram-positive pathogens could be identified. With this in mind, Influx, Inc., is currently developing clinically useful inhibitors of multidrug transporters.


    ACKNOWLEDGMENTS

This work was supported by grants 1R43AI43076-01 and 2R44GM55449-02 from the NIH.

I thank Alexander Neyfakh for advice on the manuscript.


    FOOTNOTES

* Mailing address: Influx, Inc., Chicago Technology Park, Suite 116, 2201 West Campbell Park Dr., Chicago, IL 60612. Phone: (312) 492-7760. Fax: (312) 413-9303. E-mail: pmarkham{at}uic.edu.


    REFERENCES
Top
Abstract
Text
References

1. Ahmed, M., L. Lyass, P. N. Markham, S. S. Taylor, N. Vázquez-Laslop, and A. A. Neyfakh. 1995. Two highly similar multidrug transporters of Bacillus subtilis whose expression is differentially regulated. J. Bacteriol. 177:3904-3910[Abstract/Free Full Text].
2. Baranova, N. N., and A. A. Neyfakh. 1997. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1396-1398[Abstract].
3. Bolhuis, H., G. Poelarands, H. W. van Veen, B. Poolman, A. J. M. Driessen, and W. N. Konings. 1995. The lactococcal lmrP gene encodes a proton motive force-dependent drug transporter. J. Biol. Chem. 270:26092-26098[Abstract/Free Full Text].
4. Brenwald, N. P., M. J. Gill, and R. Wise. 1997. The effect of reserpine, an inhibitor of multi-drug efflux pumps, on the in vitro susceptibilities of fluoroquinolone-resistant strains of Streptococcus pneumoniae to norfloxacin. J. Antimicrob. Chemother. 40:458-460[Free Full Text].
5. Brenwald, N. P., M. J. Gill, and R. Wise. 1998. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:2032-2035[Abstract/Free Full Text].
6. Kaatz, G. W., and S. M. Seo. 1995. Inducible NorA-mediated multidrug resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 39:2650-2655[Abstract].
7. Markham, P. N., and A. A. Neyfakh. 1996. Inhibition of the multidrug transporter NorA prevents emergence of norfloxacin resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:2673-2674[Medline].
8. Muñoz, R., and A. G. De La Campa. 1996. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob. Agents Chemother. 40:2252-2257[Abstract].
9. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Villanova, Pa.
10. Neyfakh, A. A., V. E. Bidnenko, and L. B. Chen. 1991. Efflux-mediated multidrug resistance in Bacillus subtilis: similarities and dissimilarities with the mammalian system. Proc. Natl. Acad. Sci. USA 88:4781-4785[Abstract/Free Full Text].
11. Takiff, H. E., M. Cinuino, M. C. Musso, T. Weisbrod, R. Martinez, L. Salazar, B. R. Bloom, and W. R. Jacobs. 1996. Efflux pumps of the proton antiporter family confer low level fluoroquinolone resistance in Mycobacterium smegmatis. Proc. Natl. Acad. Sci. USA 93:362-366[Abstract/Free Full Text].
12. van Veen, H. W., K. Venema, H. Bolhuis, I. Oussenka, J. Kok, B. Poolman, A. J. M. Driessen, and W. N. Konings. 1996. Multidrug resistance mediated by a bacterial homolog of the human multidrug transporter MDR1. Proc. Natl. Acad. Sci. USA 93:10668-10672[Abstract/Free Full Text].
13. Yoshida, H., M. Bogaki, S. Nakamura, K. Ubukata, and M. Konno. 1990. Nucleotide sequence and characterization of the Staphylococcus aureus norA gene, which confers resistance to quinolones. J. Bacteriol. 172:6942-6949[Abstract/Free Full Text].
14. Zeller, V., C. Janoir, M.-D. Kitzis, L. Gutmann, and N. J. Moreau. 1997. Active efflux as a mechanism of resistance to ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 41:1973-1978[Abstract].

Antimicrobial Agents and Chemotherapy, April 1999, p. 988-989, Vol. 43, No. 4
0066-4804/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Fange, D., Nilsson, K., Tenson, T., Ehrenberg, M. (2009). Drug efflux pump deficiency and drug target resistance masking in growing bacteria. Proc. Natl. Acad. Sci. USA 106: 8215-8220 [Abstract] [Full Text]  
  • Louie, A., Brown, D. L., Liu, W., Kulawy, R. W., Deziel, M. R., Drusano, G. L. (2007). In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 3988-4000 [Abstract] [Full Text]  
  • DeMarco, C. E., Cushing, L. A., Frempong-Manso, E., Seo, S. M., Jaravaza, T. A. A., Kaatz, G. W. (2007). Efflux-Related Resistance to Norfloxacin, Dyes, and Biocides in Bloodstream Isolates of Staphylococcus aureus. Antimicrob. Agents Chemother. 51: 3235-3239 [Abstract] [Full Text]  
  • Stavri, M., Piddock, L. J. V., Gibbons, S. (2007). Bacterial efflux pump inhibitors from natural sources. J Antimicrob Chemother 59: 1247-1260 [Abstract] [Full Text]  
  • Romanova, N. A., Wolffs, P. F. G., Brovko, L. Y., Griffiths, M. W. (2006). Role of Efflux Pumps in Adaptation and Resistance of Listeria monocytogenes to Benzalkonium Chloride.. Appl. Environ. Microbiol. 72: 3498-3503 [Abstract] [Full Text]  
  • Piddock, L. J. V. (2006). Clinically Relevant Chromosomally Encoded Multidrug Resistance Efflux Pumps in Bacteria. Clin. Microbiol. Rev. 19: 382-402 [Abstract] [Full Text]  
  • Marrer, E., Schad, K., Satoh, A. T., Page, M. G. P., Johnson, M. M., Piddock, L. J. V. (2006). Involvement of the Putative ATP-Dependent Efflux Proteins PatA and PatB in Fluoroquinolone Resistance of a Multidrug-Resistant Mutant of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 685-693 [Abstract] [Full Text]  
  • Marrer, E., Satoh, A. T., Johnson, M. M., Piddock, L. J. V., Page, M. G. P. (2006). Global Transcriptome Analysis of the Responses of a Fluoroquinolone-Resistant Streptococcus pneumoniae Mutant and Its Parent to Ciprofloxacin. Antimicrob. Agents Chemother. 50: 269-278 [Abstract] [Full Text]  
  • Smith, A. M., Feldman, C., Massidda, O., McCarthy, K., Ndiweni, D., Klugman, K. P. (2005). Altered PBP 2A and Its Role in the Development of Penicillin, Cefotaxime, and Ceftriaxone Resistance in a Clinical Isolate of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 49: 2002-2007 [Abstract] [Full Text]  
  • Mullin, S., Mani, N., Grossman, T. H. (2004). Inhibition of Antibiotic Efflux in Bacteria by the Novel Multidrug Resistance Inhibitors Biricodar (VX-710) and Timcodar (VX-853). Antimicrob. Agents Chemother. 48: 4171-4176 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Piroth, L., Bergoin, E., Lequeu, C., Portier, H., Chavanet, P. (2004). In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants. J Antimicrob Chemother 54: 640-647 [Abstract] [Full Text]  
  • Longbottom, C. J., Carson, C. F., Hammer, K. A., Mee, B. J., Riley, T. V. (2004). Tolerance of Pseudomonas aeruginosa to Melaleuca alternifolia (tea tree) oil is associated with the outer membrane and energy-dependent cellular processes. J Antimicrob Chemother 54: 386-392 [Abstract] [Full Text]  
  • Croisier, D., Etienne, M., Bergoin, E., Charles, P.-E., Lequeu, C., Piroth, L., Portier, H., Chavanet, P. (2004). Mutant Selection Window in Levofloxacin and Moxifloxacin Treatments of Experimental Pneumococcal Pneumonia in a Rabbit Model of Human Therapy. Antimicrob. Agents Chemother. 48: 1699-1707 [Abstract] [Full Text]  
  • Webber, M. A., Piddock, L. J. V. (2003). The importance of efflux pumps in bacterial antibiotic resistance. J Antimicrob Chemother 51: 9-11 [Full Text]  
  • Gibbons, S., Oluwatuyi, M., Kaatz, G. W. (2003). A novel inhibitor of multidrug efflux pumps in Staphylococcus aureus. J Antimicrob Chemother 51: 13-17 [Abstract] [Full Text]  
  • Yokota, S.-i., Sato, K., Kuwahara, O., Habadera, S., Tsukamoto, N., Ohuchi, H., Akizawa, H., Himi, T., Fujii, N. (2002). Fluoroquinolone-Resistant Streptococcus pneumoniae Strains Occur Frequently in Elderly Patients in Japan. Antimicrob. Agents Chemother. 46: 3311-3315 [Abstract] [Full Text]  
  • Croisier, D., Chavanet, P., Lequeu, C., Ahanou, A., Nierlich, A., Neuwirth, C., Piroth, L., Duong, M., Buisson, M., Portier, H. (2002). Efficacy and pharmacodynamics of simulated human-like treatment with levofloxacin on experimental pneumonia induced with penicillin-resistant pneumococci with various susceptibilities to fluoroquinolones. J Antimicrob Chemother 50: 349-360 [Abstract] [Full Text]  
  • Madaras-Kelly, K. J., Daniels, C., Hegbloom, M., Thompson, M. (2002). Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae. J Antimicrob Chemother 50: 211-218 [Abstract] [Full Text]  
  • Raherison, S., Gonzalez, P., Renaudin, H., Charron, A., Bebear, C., Bebear, C. M. (2002). Evidence of Active Efflux in Resistance to Ciprofloxacin and to Ethidium Bromide by Mycoplasma hominis. Antimicrob. Agents Chemother. 46: 672-679 [Abstract] [Full Text]  
  • Pestova, E., Millichap, J. J., Siddiqui, F., Noskin, G. A., Peterson, L. R. (2002). Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae. J Antimicrob Chemother 49: 553-556 [Abstract] [Full Text]  
  • Fukuda, H., Kishii, R., Takei, M., Hosaka, M. (2001). Contributions of the 8-Methoxy Group of Gatifloxacin to Resistance Selectivity, Target Preference, and Antibacterial Activity against Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1649-1653 [Abstract] [Full Text]  
  • Coyle, E. A., Kaatz, G. W., Rybak, M. J. (2001). Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother. 45: 1654-1659 [Abstract] [Full Text]  
  • Linde, H.-J., Schmidt, M., Fuchs, E., Reischl, U., Niller, H.-H., Lehn, N. (2001). In Vitro Activities of Six Quinolones and Mechanisms of Resistance in Staphylococcus aureus and Coagulase-Negative Staphylococci. Antimicrob. Agents Chemother. 45: 1553-1557 [Abstract] [Full Text]  
  • Silva, P. E. A., Bigi, F., de la Paz Santangelo, M., Romano, M. I., Martín, C., Cataldi, A., Aínsa, J. A. (2001). Characterization of P55, a Multidrug Efflux Pump in Mycobacterium bovis and Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 45: 800-804 [Abstract] [Full Text]  
  • Boos, M., Mayer, S., Fischer, A., Köhrer, K., Scheuring, S., Heisig, P., Verhoef, J., Fluit, A. C., Schmitz, F.-J. (2001). In Vitro Development of Resistance to Six Quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus. Antimicrob. Agents Chemother. 45: 938-942 [Abstract] [Full Text]  
  • Lomovskaya, O., Warren, M. S., Lee, A., Galazzo, J., Fronko, R., Lee, M., Blais, J., Cho, D., Chamberland, S., Renau, T., Leger, R., Hecker, S., Watkins, W., Hoshino, K., Ishida, H., Lee, V. J. (2001). Identification and Characterization of Inhibitors of Multidrug Resistance Efflux Pumps in Pseudomonas aeruginosa: Novel Agents for Combination Therapy. Antimicrob. Agents Chemother. 45: 105-116 [Abstract] [Full Text]  
  • Putman, M., van Veen, H. W., Konings, W. N. (2000). Molecular Properties of Bacterial Multidrug Transporters. Microbiol. Mol. Biol. Rev. 64: 672-693 [Abstract] [Full Text]  
  • Poole, K. (2000). Efflux-Mediated Resistance to Fluoroquinolones in Gram-Positive Bacteria and the Mycobacteria. Antimicrob. Agents Chemother. 44: 2595-2599 [Full Text]  
  • Martinez, J. L., Baquero, F. (2000). Mutation Frequencies and Antibiotic Resistance. Antimicrob. Agents Chemother. 44: 1771-1777 [Full Text]  
  • Pestova, E., Millichap, J. J., Noskin, G. A., Peterson, L. R. (2000). Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones. J Antimicrob Chemother 45: 583-590 [Abstract] [Full Text]  
  • Beyer, R., Pestova, E., Millichap, J. J., Stosor, V., Noskin, G. A., Peterson, L. R. (2000). A Convenient Assay for Estimating the Possible Involvement of Efflux of Fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: Evidence for Diminished Moxifloxacin, Sparfloxacin, and Trovafloxacin Efflux. Antimicrob. Agents Chemother. 44: 798-801 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Markham, P. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Markham, P. N.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»